Coskun U, Yamac D, Gulbahar O, Sancak B, Karaman N, Ozkan S
Gazi University Medical School, Department of Medical Oncology, Ankara, Turkey.
Neoplasma. 2007;54(4):348-52.
Serum levels of YKL-40, MMP-2 and MMP-9 in 27 patients with locally advanced breast carcinoma received neoadjuvant chemotherapy were measured. All patients underwent neoadjuvant chemotherapy named as FAC protocol (5-Fluorouracil, Doxorubicin and Cyclophosphamide) with 21 days interval. There was 26,7% decrease in mean serum YKL-40 levels (from 146,4 microg/ml to 107,3 microg/ml) in clinically responsive group. This level was almost unchanged in non-responsive group (P>0, 05). There was 42, 1% decrease in mean serum YKL-40 levels (from 173,1 microg/ml to 98, 8 microg/ml) in pathologically responsive group. This decrease was more dramatic in patients with complete pathological response (70, 2%). However, this level was slightly increased in non-responsive group. Changes in serum levels of MMP-2 and MMP-9 were not found to be associated with tumor response. Serum measurement of YKL-40 can be a helpful tool to predict pathological tumor response in breast cancer patients with neoadjuvant chemotherapy but not MMP-2 and MMP-9.
检测了27例接受新辅助化疗的局部晚期乳腺癌患者血清中YKL-40、基质金属蛋白酶-2（MMP-2）和基质金属蛋白酶-9（MMP-9）的水平。所有患者均接受名为FAC方案（氟尿嘧啶、阿霉素和环磷酰胺）的新辅助化疗，化疗间隔为21天。临床反应组患者血清YKL-40平均水平下降了26.7%（从146.4μg/ml降至107.3μg/ml）。在无反应组中该水平几乎未变（P>0.05）。病理反应组患者血清YKL-40平均水平下降了42.1%（从173.1μg/ml降至98.8μg/ml）。在完全病理缓解的患者中这种下降更为显著（70.2%）。然而，在无反应组中该水平略有升高。未发现MMP-2和MMP-9血清水平的变化与肿瘤反应相关。血清YKL-40检测可作为预测接受新辅助化疗的乳腺癌患者病理肿瘤反应的有用工具，但MMP-2和MMP-9则不然。
